reports
ServisFirst Bank Unveils Sweeping Leadership Advancements Companywide
ServisFirst Bank Unveils Sweeping Leadership Advancements Companywide New Executive Appointments Position the Bank for Continued Momentum BIRMINGHAM, Ala., Dec. 15, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bank, a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce a series of significant leadership appointments as the Bank continues to expand its strategic footprint, deepen client relationships, and position itself for long-term growth. The new leadership announcements include Hal Clemmer as Chief Banking Officer; Bart McBride as Sales Manager; and Harrison Morris as R...
ServisFirst Bank Announces Expansion into Texas
ServisFirst Bank Announces Expansion into Texas Christopher Dvorachek Appointed Regional CEO, Texas HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bank, a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce its expansion into Texas with the opening of a new office in Houston. This strategic move marks a significant milestone in the Bank’s continued growth and reflects its commitment to serving clients in one of the country’s most dynamic commercial markets. To lead the Bank’s entry into Texas, ServisFirst Bank has appointed Christopher Dvorachek as Regional...
ServisFirst Bank Huntsville Announces New Regional CEO, Executive Vice...
ServisFirst Bank Huntsville Announces New Regional CEO, Executive Vice President Experienced Banking Leader, Jim Holtkamp, to Guide Huntsville Growth and Strategy HUNTSVILLE, Ala., Dec. 15, 2025 (GLOBE NEWSWIRE) -- , a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce the appointment of Jim Holtkamp as Regional CEO, Huntsville and Executive Vice President. In this new role, Holtkamp will lead the Bank’s regional banking strategy, commercial market expansion, and client-focused growth initiatives across North Alabama. “Jim has played an essential role in the devel...
ServisFirst Bancshares, Inc. Increases Quarterly Cash Dividend by 13.4...
ServisFirst Bancshares, Inc. Increases Quarterly Cash Dividend by 13.4% BIRMINGHAM, Ala., Dec. 15, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc., (NYSE: SFBS) (“ServisFirst”), the holding company for ServisFirst Bank, today announces: At a meeting held on December 15, 2025, its Board of Directors increased the company’s quarterly cash dividend from $0.335 per share to $0.38 per share. The dividend is payable on January 13, 2026 to stockholders of record as of January 2, 2026. ServisFirst has increased its dividend annually since the company went public in 2014. About ServisFir...
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recu...
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A preliminary analysis of recurrence rates by two methods...
Greenwich LifeSciences Announces Completion of Enrollment in the Open ...
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screenin...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its scr...
ServisFirst Bancshares, Inc. Announces Results For Third Quarter of 20...
ServisFirst Bancshares, Inc. Announces Results For Third Quarter of 2025 BIRMINGHAM, Ala., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc. (NYSE: SFBS), today announced earnings and operating results for the quarter ended September 30, 2025. Third Quarter 2025 Highlights: Diluted earnings per share of $1.20 for the quarter. Adjusted diluted earnings per share of $1.30, up 18.2% from the third quarter of 2024.Net interest margin of 3.09%, up 25 basis points from the third quarter of 2024 (negatively impacted by about 10 bps on a single non-accrual relationship).Adjusted co...
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Cl...
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Austria. The Company's application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in addition to ...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 C...
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition...
ServisFirst Bancshares, Inc. to Announce Third Quarter 2025 Financial ...
ServisFirst Bancshares, Inc. to Announce Third Quarter 2025 Financial Results October 20th BIRMINGHAM, Ala., Sept. 26, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc. (NYSE: SFBS) is scheduled to announce earnings and operating results for the quarter ended September 30, 2025 on October 20, 2025 at 4 p.m. ET. The news release will be available at . ServisFirst Bancshares, Inc. will host a live audio webcast to discuss earnings and results on Monday, October 20, 2025 beginning at 5:15 p.m. ET. The audio webcast can be accessed at . A replay of the call will be available until Octobe...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...
ServisFirst Bancshares, Inc. Declares Third Quarter Cash Dividend
ServisFirst Bancshares, Inc. Declares Third Quarter Cash Dividend BIRMINGHAM, Ala., Sept. 15, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc., (NYSE: SFBS) (“ServisFirst”), the holding company for ServisFirst Bank, today announces: At a meeting held on September 15, 2025, its Board of Directors declared a quarterly cash dividend of $0.335 per share, payable on October 10, 2025, to stockholders of record as of October 1, 2025. About ServisFirst Bancshares, Inc. ServisFirst Bancshares, Inc. is a bank holding company based in Birmingham, Alabama. Through its subsidiary ServisFirst Ba...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...
ServisFirst Bancshares Inc: 1 director
A director at ServisFirst Bancshares Inc sold 22,206 shares at 87.990USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich ...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical O...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate E...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.